---
company: Inhibikase Therapeutics, Inc.
ticker: IKT
form: 8-K
filed: 2026-05-12
accession: 0001193125-26-219610
source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/
---

# Inhibikase Therapeutics (IKT) earnings release, May 12, 2026

Inhibikase Therapeutics, Inc. (IKT) · Form 8-K, Item 2.02 · Filed 2026-05-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/)

Inhibikase Therapeutics Announces First Quarter 2026

Financial Results and Highlights Recent Activity

WILMINGTON, Del., May 12, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or

“Company”), a clinical-stage pharmaceutical company developing

IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31,

2026, and highlighted recent developments.

“We were excited to enroll the first patient in our registrational

IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites, including being one of the first companies to successfully take advantage of the new European Medicines Agency

FAST-EU

(Facilitating and Accelerating Strategic Trials in the European Union) initiative to accelerate multinational clinical trials,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “With the recent approvals obtained in the first 16 countries worldwide, Inhibikase is well-positioned to initiate clinical site activations and seek to advance enrollment of

IMPROVE-PAH.

Later this week, we also look forward to the first of two new presentations of Phase 1 and pre-clinical studies of

IKT-001 at the

American Thoracic Society International Conference, to be held in Orlando, Florida.”

Recent Developments¹

Upcoming Presentations

Financial Results

Cash Position:

As of March 31, 2026, cash, cash equivalents and marketable securities were $170.4 million.

Net Loss:

Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.

R&D Expenses:

Research and development expenses were $10.8 million for the quarter ended March 31, 2026, compared to $10.5 million for the quarter ended March 31, 2025, which included a one-time

(non-cash) charge of

$7.4 million for the acquired IPR&D related to the CorHepta acquisition.

SG&A Expenses:

Selling, general and administrative expenses for the quarter ended March 31, 2026 were $7.4 million, compared to $5.2 million for the quarter ended March 31, 2025.

About

Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as

“c-Kit,” has been implicated. Our lead product candidate is

IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named

IMPROVE-PAH

(

I

KT-001 for

M easuring

P ulmonary Vascular

R esistance and

O utcome

V ariables in a Phase 3

E valuation of

PAH), is actively enrolling patients.²

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases,

SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under

Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,”

“will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of

IKT-001, the advancement of the Company’s global pivotal Phase 3 clinical study of

IKT-001 in PAH, including the timing, design, and conduct of the

IMPROVE-PAH study and related regulatory submissions, the Company’s ability to obtain additional regulatory approvals for the

IMPROVE-PAH study, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of

IKT-001, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate

IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form

10-K and Form

10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release... (truncated)nformation, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Investor

Relations:

Michael Moyer

LifeSci Advisors mmoyer@lifesciadvisors.com —tables to follow—³

Inhibikase Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)⁴

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

## Financial statements

### Income Statement (Three months ended March 31, — (Unaudited))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Costs and expenses: | Research and development | 10,839,150 | 10,513,579 |
| Costs and expenses: | Selling, general and administrative | 7,376,123 | 5,249,291 |
| Costs and expenses: | Change in fair value contingent consideration | -373,354 | -1,164,864 |
| Costs and expenses: | Total costs and expenses | 17,841,919 | 14,598,006 |
| Costs and expenses: | Loss from operations | -17,841,919 | -14,598,006 |
| Costs and expenses: | Other income | 1,461,079 | 919,271 |
| Costs and expenses: | Net loss | -16,380,840 | -13,678,735 |
| Other comprehensive income (loss), net of tax | Unrealized gain (loss) on marketable securities | -48,095 | 36,281 |
| Other comprehensive income (loss), net of tax | Comprehensive loss | -16,428,935 | -13,642,454 |
| Other comprehensive income (loss), net of tax | Net loss per share – basic and diluted | -0.1 | -0.15 |
| Other comprehensive income (loss), net of tax | Weighted-average number of shares – basic and diluted | 172,306,932 | 89,537,171 |

### Balance Sheet (March 31, 2026 — (Unaudited))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 49,573,510 | 139,220,208 |
| Current assets: | Marketable securities | 120,795,235 | 39,543,820 |
| Current assets: | Prepaid research and development | 514,910 | 1,001,993 |
| Current assets: | Prepaid expenses and other current assets | 1,292,813 | 343,374 |
| Current assets: | Total current assets | 172,176,468 | 180,109,395 |
| Current assets: | Prepaid research and development, noncurrent | 1,000,000 | 1,000,000 |
| Current assets: | Other assets | 155,759 | 95,121 |
| Current assets: | Total assets | 173,332,227 | 181,204,516 |
| Current liabilities: | Accounts payable | 1,587,305 | 1,158,054 |
| Current liabilities: | Accrued expenses and other current liabilities | 4,124,654 | 4,081,282 |
| Current liabilities: | Contingent consideration liability |  | 3,061,501 |
| Current liabilities: | Total current liabilities | 5,711,959 | 8,300,837 |
| Current liabilities: | Total liabilities | 5,711,959 | 8,300,837 |
| Stockholders’ equity: | Common stock, $0.001 par value; 500,000,000 shares authorized; 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 10) at March 31, 2026 and December 31, 2025, respectively | 132,032 | 131,691 |
| Stockholders’ equity: | Additional paid-in capital | 326,575,169 | 315,429,986 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | -26,293 | 21,802 |
| Stockholders’ equity: | Accumulated deficit | -159,060,640 | -142,679,800 |
| Stockholders’ equity: | Total stockholders’ equity | 167,620,268 | 172,903,679 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 173,332,227 | 181,204,516 |

### Cash Flow (Three months ended March 31, — (Unaudited))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Cash flows from operating activities | Net loss | -16,380,840 | -13,678,735 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation |  | 12,654 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation expense | 5,559,766 | 2,042,196 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Write-off of in-process research and development |  | 7,357,294 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Change in fair value contingent consideration | -373,354 | -1,164,864 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Non-cash accretion on marketable securities | -814,923 |  |
| Changes in operating assets and liabilities: | Operating lease right-of-use assets |  | 32,718 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | -949,439 | -211,924 |
| Changes in operating assets and liabilities: | Prepaid research and development | 487,083 | 28,833 |
| Changes in operating assets and liabilities: | Other assets | -60,638 |  |
| Changes in operating assets and liabilities: | Accounts payable | 429,251 | 680,824 |
| Changes in operating assets and liabilities: | Operating lease liabilities |  | -35,745 |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | 43,372 | 833,219 |
| Changes in operating assets and liabilities: | Net cash used in operating activities | -12,059,722 | -4,103,530 |
| Cash flows from investing activities | Purchases of equipment and improvements |  | -13,399 |
| Cash flows from investing activities | Purchases of investments - marketable securities | -90,584,587 |  |
| Cash flows from investing activities | Maturities of investments - marketable securities | 10,100,000 | 21,506,365 |
| Cash flows from investing activities | Acquired in-process research and development |  | -438,624 |
| Cash flows from investing activities | Net cash provided by (used in) investing activities | -80,484,587 | 21,054,342 |
| Cash flows from financing activities | Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 2,897,611 |  |
| Cash flows from financing activities | Net cash provided by financing activities | 2,897,611 |  |
| Cash flows from financing activities | Net increase (decrease) in cash and cash equivalents | -89,646,698 | 16,950,812 |
| Cash flows from financing activities | Cash and cash equivalents at beginning of period | 139,220,208 | 56,490,579 |
| Cash flows from financing activities | Cash and cash equivalents at end of period | 49,573,510 | 73,441,391 |
| Supplemental disclosures of cash flow information | Issuance costs | 85,000 | $— |
| Non-cash investing and financing activities | Contingent consideration | $— | 3,270,579 |
| Non-cash investing and financing activities | Settlement of contingent consideration liability | 2,688,147 | $— |
